A new study shows that the TissueCypher Barrett's Esophagus test significantly improves management of patients by nearly doubling appropriate care escalation for those at high risk of progressing to esophageal cancer, while reducing overtreatment in low-risk patients. The test uses advanced molecular analysis to better predict which patients with non-dysplastic Barrett's esophagus will develop serious conditions, enabling earlier and more precise interventions. This advancement could lead to better patient outcomes and more efficient use of medical resources in managing Barrett's esophagus.
TissueCypher Barrett's Esophagus test is the subject, with Pluang market data providing context. For readers following the health sector, here is Pluang's market snapshot as of Sep 15, 2026 16:41 WIB: Of 91 priced US health stocks, 35 rose and 48 fell. Notable movers include ACB at USD 3.92 (+2.89%), ENVB at USD 1.46 (-2.67%), and INO at USD 1.21 (+2.54%).
Coherent's stock valuation has fallen about 28% from its peak in June 2026, yet the company shows strong financial health with a 42% revenue increase, 200 basis points improvement in gross margin, and a 74% rise in earnings per share year-over-year. ...
XRP Ledger's proposed Batch V1.1 upgrade, which allows up to eight dependent transactions per block, is one vote away from activation with 27 of 35 validators in favor. This upgrade aims to improve scalability and transaction throughput, potentially ...
Boston Scientific (BSX) has been upgraded to a 'Strong Buy' rating due to its current undervaluation, trading at a forward P/E of 13.1, which is below its historical average. Despite some growth challenges in WATCHMAN and electrophysiology segments, ...
Target announced its Target Circle Deal Days event from October 6-7, offering up to 40% off thousands of items including fall apparel, home decor, beauty products, toys, and tech. Early access starts October 5 for paid Target Circle 360 members. The ...
WestGold Metals has agreed to sell its option to acquire the Isoneva gold property in Finland to Jesmond Capital, marking a strategic shift to focus solely on North American exploration projects. The deal includes cash payments and shares in Jesmond,...
